V. Guallar

VLP-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice

This study develops a neoantigen selection pipeline and a VLP-based vaccine platform to enhance immunogenicity and antitumor activity in mice.

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

Are Deep Learning Structural Models Sufficiently Accurate for Virtual Screening? Application of Docking Algorithms to AlphaFold2 Predicted Structures

This study evaluates the accuracy of AlphaFold2 structures for virtual screening, finding that out-of-the-box models are insufficient for hit-finding in low sequence identity targets and suggest post-processing improvements.

Are Deep Learning Structural Models Sufficiently Accurate for Free Energy Calculations? Application of FEP+ to AlphaFold2 Predicted Structures

The paper assesses if AlphaFold2 structures are accurate enough for FEP calculations in drug discovery, finding they perform comparably to X-ray structures in most cases.

SARS-CoV-2 B.1.351 (beta) variant shows enhanced infectivity in K18-hACE2 transgenic mice and expanded tropism to wildtype mice compared to B.1 variant

This study shows that the SARS-CoV-2 B.1.351 variant infects K18-hACE2 mice faster and wildtype mice, with milder symptoms than the B.1 variant.

Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses

This study shows Siglec-1 on APCs mediates SARS-CoV-2 trans-infection and triggers proinflammatory responses, suggesting it as a potential therapeutic target.

Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals.

The paper assesses how prior SARS-CoV-2 infection affects B.1.1.7 cross-neutralization in vaccinated individuals, finding that previously infected individuals show equivalent neutralization against B.1.1.7 compared to the Wuhan strain.

Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in hamsters

This study shows that hamsters infected with SARS-CoV-2 are not fully protected against reinfection with both original and variant isolates, but experience reduced lung disease severity upon re-exposure.

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

This study tracks neutralizing antibody levels in COVID-19 patients up to six months post-infection, finding persistent activity in mild cases and a slower decline in hospitalized individuals.

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect after a Drug Repurposing Screen

This study screens existing drugs to identify potent inhibitors of SARS-CoV-2-induced cytopathic effect and viral replication, finding plitidepsin as the most effective clinically approved drug.